Q1 FY27 revenue up 25 percent, EBITDA up 37 percent YoY

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDF

JUBLINGREA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.6%1-day move

₹764.40

prior close

₹721.10

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.6-0.0+1.3+2.3-3.6-5.2-2.5-5.1——————

Up moveDown movePending

AI summary

Jubilant Ingrevia posted strong Q1 FY27 results. Revenue rose 25 percent YoY to Rs 1,300 crore; EBITDA up 37 percent to Rs 209 crore with margins at 16 percent. PAT grew 41 percent YoY to Rs 106 crore. Chemical Intermediates EBITDA surged 240 percent YoY on better pricing; Nutrition hit 3-year high EBITDA, up 45 percent. Management guides sequential improvement ahead, with growth led by Specialty Chemicals and Nutrition. CDMO pipeline has 100 plus molecules worth over Rs 3,500 crore peak potential.

Likely market impact

Highest revenue and EBITDA in 15 plus quarters; positive guidance and strong pipeline support continued growth momentum for shareholders.